• Users Online: 116
  • Print this page
  • Email this page

Table of Contents
Year : 2022  |  Volume : 33  |  Issue : 2  |  Page : 47-48


Department of Urology, The Center of Excellence in Shockwave Medicine and Tissue Regeneration, Kaohsiung Chang Gung Memorial Hospital; College of Medicine, Chang Gung University, Kaohsiung, Taiwan

Date of Submission28-Mar-2022
Date of Acceptance28-Mar-2022
Date of Web Publication09-Jun-2022

Correspondence Address:
Yao-Chi Chuang
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/UROS.UROS_36_22

Rights and Permissions

How to cite this article:
Chuang YC. Editorial. Urol Sci 2022;33:47-8

How to cite this URL:
Chuang YC. Editorial. Urol Sci [serial online] 2022 [cited 2023 Jan 31];33:47-8. Available from: https://www.e-urol-sci.com/text.asp?2022/33/2/47/347054

Dear Colleagues,

Being an elite urologist is arduous. Having to keep up with the latest research in one's field is grueling but necessary. We hope that Urological Sciences makes it easier for readers to stay up-to-date with the latest clinical research in urology.

Bladder neck contracture (BNC) is one of the most frequent postsurgical complications while treating prostate diseases, the incidence rate of which varies depending on the type of surgical treatment adopted. The treatment options for BNC range from endoscopic interventions to complex (abdominal) surgical approaches. Abbosov et al. have published a review of various alternative surgical methods for treating BNC, including transurethral resection and incision of the bladder neck.

Lai et al. evaluated the correlation between the outcomes of a post-robot-assisted radical prostatectomy (RARP) by a single experienced surgeon at the E-DA Hospital and the interval after biopsy (≤4 weeks, 4–8 weeks, and ≥8 weeks). They found that RARP can be effectively and safely performed at various time intervals after a prostate biopsy without increasing the total operative time or adversely compromising postoperative functional and oncologic outcomes. However, performing RARP at <4 weeks after prostate biopsy had a risk of increased blood loss.

Wu et al. analyzed the socioeconomic distribution pattern of the incidence of and mortality after urological cancer in Taiwan using data from the National Health Insurance. They designed a retrospective longitudinal cohort study of 3686 subjects who were newly diagnosed with bladder cancer (BC), kidney cancer (KC), and upper urinary tract cancer (UTUC) between 2000 and 2010. Interestingly, their results revealed that KC tends to occur in patients involved in higher-income occupations who reside in urban areas. In contrast, both BC and UTUC were much more prevalent in patients with poorer socioeconomic means and those living in rural areas. Accordingly, the authors suggested that the higher incidence of urothelial cancer in these areas may be explained by their exposure to occupation-related carcinogens and other environmental factors, such as arsenic-compound water contamination and aristolochicbased Chinese traditional herbal medicines.

Chang et al. compared the safety and efficacy of monopolar transurethral resection of the prostate (M-TURP) and holmium laser enucleation of the prostate (HOLEP) for a prostate size of >100 ml. Their data revealed that both M-TURP and HOLEP performed in men with prostate volume >100 ml had comparable operative times, length of hospital stay, and postoperative functional outcomes. However, higher transfusion rates and postoperative hyponatremia were noted after MTURP compared with HOLEP. Therefore, HOLEP provides an efficient and safer method for patients with large benign hypertrophy of the prostate.

Tampubolon et al. measured the correlation between tumor depth and width and lymphovascular invasion (LVI) in nonmuscle invasive BC (NMIBC) in a 5-year retrospective analytical study (2015–2019). Their study included 64 patients with a pT1 BC. They reported that the overall mean tumor pT1 invasion depth was 2.03 ± 0.918 mm. The non-LVI group's mean tumor invasion depth was 1.72 ± 0.721 mm, whereas the LVI group had a mean depth of 2.21 ± 0.980 mm. Notably, the tumor invasion depth was a significant factor for LVI, whereas the tumor's maximum diameter was not. They concluded that measuring the pT1 tumor invasion depth may serve as an important predictor of tumor recurrence and progress.

At present, only a few published models are used for predicting functional outcomes following partial or radical nephrectomy. Ooi et al. evaluated the reliability and validity of a new baseline renal function calculator model based on the preoperative estimated glomerular filtration rate (eGFR), type of surgery, patient's age, tumor size, and presence of diabetes after radical nephrectomy in 52 Malaysian patients. The mean preoperative eGFR was 85.33 mL/min/1.73 m2, whereas the mean postoperative eGFR was 59.88 mL/min/1.73 m2. They observed that the predicted eGFR was significantly correlated with the actual eGFR 6 months after radical nephrectomy (r = 0.837, P < 0.0001), and good reliability of the formula was observed (intraclass correlation coefficient = 0.83). Hence, this novel, reliable, and valid baseline renal function calculator can provide an easy and rapid estimate of the renal function in patients scheduled for radical nephrectomy.

There are several bacillus Calmette–Guérin (BCG) strains used in clinical practice for treating NMIBC, the two most common of which are ImmuCyst® (Sanofi Pasteur, France) from the Connaught strain and OncoTICE® (Merck, USA) from the TICE strain. Kuo et al. compared the efficacy of these two BCG strains in 730 patients with NMIBC. Their results showed that both BCG strains had comparable efficacy in reducing the recurrence of bladder tumors in patients with NMIBC. Both strains resulted in recurrence-free survival rates similar to those of chemotherapeutic agents.

Finally, sildenafil, potent and selective phosphodiesterase type 5 inhibitors, can effectively treat erectile dysfunction in addition to its potential use in treating male idiopathic infertility. Mokhtari et al. conducted a randomized, controlled, double-blinded, crossover clinical trial to evaluate the effects of oral sildenafil on semen parameters in male participants with idiopathic infertility. However, their results showed no significant change in sperm parameters in male patients receiving sildenafil for treating idiopathic infertility.

We hope that you find these articles relevant in expanding your knowledge base about urology.


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded168    
    Comments [Add]    

Recommend this journal